-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 18, Sidi Medicine announced that its multi-center, open-label Phase 1b/2 clinical trial application for 3D229 injection combined with envolimab injection or lenvatinib in the treatment of advanced solid tumors was approved in China
Screenshot source: CDE official website
Studies have shown that the GAS6-AXL signaling pathway is a key pathway that promotes tumor growth and metastasis, tumor immune escape and drug tolerance
According to the earlier public information of Sidi Medicine, 3D229 (also known as: AVB-500) is the core anti-cancer product of Aravive
This approval is a Phase 1b/2 clinical study in patients with advanced solid tumors of non-small cell lung cancer, clear renal cell carcinoma and urothelial carcinoma, which aims to evaluate the efficacy of 3D229 injection in combination with Envolitinib alone.